{"id":295533,"date":"2026-02-05T00:00:00","date_gmt":"2026-02-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0011-2024-biopharma-painful-diabetic-neuropathy-unmet-need-unmet-need-painful-diabetic\/"},"modified":"2026-03-31T10:23:33","modified_gmt":"2026-03-31T10:23:33","slug":"unnecg0011-2026-biopharma-painful-diabetic-neuropathy-unmet-need-unmet-need-painful-diabetic-neuropathy-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0011-2026-biopharma-painful-diabetic-neuropathy-unmet-need-unmet-need-painful-diabetic-neuropathy-us-eu\/","title":{"rendered":"Painful Diabetic Neuropathy &#8211; Unmet Need &#8211; Unmet Need &#8211; Painful Diabetic Neuropathy (US\/EU)"},"content":{"rendered":"<div>\n<p>Painful diabetic neuropathy (<abbr title=\"painful diabetic neuropathy\">PDN<\/abbr>) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and numbness, particularly in the feet and legs. Risk factor reduction, lifestyle modifications, and pharmacological treatments are all used to prevent and manage pain symptoms. Only a few pharmacological therapies are approved to treat <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr>, and most are generically available, including pregabalin (Lyrica), duloxetine (Cymbalta), and gabapentin (Neurontin). Approved branded therapies with novel delivery profiles, such as Averitas\u2019s Qutenza (capsaicin topical system), have struggled to gain a foothold in the market, indicating an opportunity for developers in the <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr> market to prioritize agents that can address existing unmet needs while demonstrating superior efficacy, safety, and tolerability. Understanding prescriber perceptions and decision drivers in <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr> can aid drug developers in identifying strategies for new product positioning and differentiation.<\/p>\n<\/div>\n<div>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<\/div>\n<ul class=\"BulletListStyle1 SCXP149595375 BCX0 round-bullets\">\n<li>Which clinical endpoints and drug attributes are most influential in prescribing for <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr>? How do neurologists rate the performance of key drugs on these attributes?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new <abbr title=\"painful diabetic neuropathy\">PDN<\/abbr> drug?<\/li>\n<\/ul>\n<div>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European neurologists fielded in February 2024<\/p>\n<p><strong>Key drugs:<\/strong> Pregabalin, duloxetine, tramadol <abbr title=\"immediate release\">IR<\/abbr>, gabapentin, amitriptyline, escitalopram, lidocaine patch<\/p>\n<p><b>PRODUCT DESCRIPTION<\/b><\/p>\n<\/div>\n<div>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/p>\n<div>\n<p><strong>KEY FEATURE<\/strong><\/p>\n<\/div>\n<div>\n<p>The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<\/div>\n<\/div>\n","protected":false},"template":"","class_list":["post-295533","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-neuropathy","biopharma-therapy-areas-painful-diabetic-neuropathy","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295533\/revisions"}],"predecessor-version":[{"id":295763,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295533\/revisions\/295763"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}